Client News
InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting
8th March 2022
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
8th March 2022
AiCuris erhält NRW-Förderung von insgesamt EUR 5,9 Mio. für die Entwicklung seines Corona-Virus-Programms zur Vorbeugung schwerer Symptome bei SARS-CoV-2-Infektionen
3rd March 2022
RedHill Announces Positive Phase 2 Study Results with Oral RHB-107 in Non-Hospitalized COVID-19
1st March 2022
InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa
28th February 2022
Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment
28th February 2022
dievini and related parties underline their strong commitment as shareholders of CureVac N.V. and do no longer plan to sell shares to the public
22nd February 2022
Andera Partners supports TargED Biopharmaceuticals in €39 million Series A financing to bring groundbreaking thrombolytic treatment to patients
22nd February 2022
Secarna Pharmaceuticals’ partner Denali Therapeutics exercises option for LNAplusTM antisense oligonucleotide development program in neurodegeneration
22nd February 2022
There is no more content to load